Spots Global Cancer Trial Database for malignant tumors
Every month we try and update this database with for malignant tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress | NCT01092247 | Malignant Tumor... | Nutritional sup... Nutritional int... | 18 Years - 85 Years | Tel-Aviv Sourasky Medical Center | |
| rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors | NCT00902122 | Advanced Malign... | rAd-p53 gene surgery p53 gene therap... p53 gene therap... | 18 Years - 85 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | NCT05615974 | Malignant Tumor... | LM101 Toripalimab Rituximab Envafolimab | 18 Years - | LaNova Medicines Limited | |
| Study Evaluating CMD-193 in Advanced Malignant Solid Tumors | NCT00161642 | Neoplasms | CMD-193 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors | NCT02534506 | Malignant Tumor... | Urelumab Nivolumab | 20 Years - | Bristol-Myers Squibb | |
| A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies | NCT00130169 | Cancer, Maligna... | E7974 | 18 Years - | Eisai Inc. | |
| rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors | NCT00902083 | Advanced Oral a... | p53 gene with s... surgery p53 with chemot... p53 gene therap... | 18 Years - 85 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors | NCT05714748 | Malignant Tumor... | EBV mRNA vaccin... | 18 Years - 70 Years | West China Hospital | |
| Study Evaluating CMD-193 in Advanced Malignant Solid Tumors | NCT00161642 | Neoplasms | CMD-193 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET | NCT03542773 | Schwannomas Malignant Tumor... | 18F-DCFPyL Inje... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Additive Homeopathy in Cancer Patients | NCT01509612 | Malignant Tumor... | Additive classi... Homeopathic Pla... | 18 Years - | Medical University of Vienna | |
| Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer | NCT00046540 | Neoplasms | Liposome-encaps... | 18 Years - | INSYS Therapeutics Inc | |
| Bioseal Dural Sealing Study BIOS-14-001 | NCT03110783 | Benign Tumors Malignant Tumor... Vascular Malfor... | Bioseal | 18 Years - | Guangzhou Bioseal Biotechnology Co., Ltd. | |
| Usefulness of Gadovist-enhanced FLAIR Imaging | NCT05293990 | Malignant Tumor... Brain Lymphoma CNS Lymphoma | Usefulness of G... | 19 Years - | Korea University Guro Hospital | |
| Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors | NCT02534506 | Malignant Tumor... | Urelumab Nivolumab | 20 Years - | Bristol-Myers Squibb | |
| Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer | NCT00046540 | Neoplasms | Liposome-encaps... | 18 Years - | INSYS Therapeutics Inc | |
| rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors | NCT00902083 | Advanced Oral a... | p53 gene with s... surgery p53 with chemot... p53 gene therap... | 18 Years - 85 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| Usefulness of Gadovist-enhanced FLAIR Imaging | NCT05293990 | Malignant Tumor... Brain Lymphoma CNS Lymphoma | Usefulness of G... | 19 Years - | Korea University Guro Hospital | |
| A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram | NCT00786838 | Solid Tumor | Trabectedin Placebo | 18 Years - 65 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram | NCT00786838 | Solid Tumor | Trabectedin Placebo | 18 Years - 65 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors | NCT04702841 | CAR Malignant Tumor... | Chimeric antige... | 14 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors | NCT03160599 | Malignant Tumor... | ketogenic diet | 18 Years - 60 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer | NCT00165100 | Malignant Tumor... Subcutaneous Tu... Lymph Node Tumo... | Dynamic Area Te... | 16 Years - | Dana-Farber Cancer Institute | |
| Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors | NCT05714748 | Malignant Tumor... | EBV mRNA vaccin... | 18 Years - 70 Years | West China Hospital | |
| Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer | NCT02041871 | Hepatectomy Elective Hepate... Malignant Tumor... | Oral immunonutr... Placebo | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors | NCT03160599 | Malignant Tumor... | ketogenic diet | 18 Years - 60 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors | NCT00902122 | Advanced Malign... | rAd-p53 gene surgery p53 gene therap... p53 gene therap... | 18 Years - 85 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors | NCT01678690 | Malignant Tumor... | Gemcitabine HCl... | 18 Years - | InnoPharmax Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
